Management ChangeApr 28, 2026, 04:09 PM
GNTA CFO Slansky Transitions to Consulting Role; US Subsidiary Closes
AI Summary
Genenta Science S.p.A. has entered into a binding consulting agreement with Richard B. Slansky, transitioning him from his employee role as CFO of its US subsidiary, Genenta Science, Inc., to a consultant CFO for the parent company. The agreement, effective April 24, 2026, with services starting June 1, 2026, will run for one year and is non-cancellable, with automatic annual renewals. Mr. Slansky will lead the closure of Genenta Science, Inc., and the company anticipates significant annual savings from this transition.
Key Highlights
- Richard B. Slansky transitions from employee CFO of Genenta Science, Inc. to consultant CFO for Genenta Science S.p.A.
- Consulting agreement effective April 24, 2026, with services commencing June 1, 2026, until May 31, 2027.
- Company will close its US subsidiary, Genenta Science, Inc., with Mr. Slansky leading the effort.
- Agreement is binding and non-cancellable, automatically renewing annually with 30-day notice.
- Consultant to receive monthly compensation and 12 months of healthcare cost coverage.
- Company expects significant annual savings from the transition of Mr. Slansky's role.
- Mr. Slansky retains CFO rights and responsibilities, reporting to the CEO and Board.
Price Impact
More from GNTA